United Kingdom likely to have Covid-19 vaccine by early 2021: Hancock

UK Health Secretary Matt Hancock claimed that a coronavirus vaccine is "most likely" to be ready in the first few months of 2021, if it gets approved

Coronavirus, vaccine, covid
Representative image
IANS London
2 min read Last Updated : Sep 08 2020 | 11:33 AM IST

UK Health Secretary Matt Hancock claimed that a coronavirus vaccine is "most likely" to be ready in the first few months of 2021, if it gets approved.

In a statement on Monday, Hancock said it was "looking up" that the vaccine being developed by experts at the University of Oxford and pharmaceutical giant AstraZeneca would be granted approval for use soon after trials in several countries, including the UK, the US and Brazil, Xinhua news agency reported.

His statement came at a time when countries, such as the UK, China, Russia and the US, are engaged in a race against time to develop a vaccine for the novel coronavirus.

The manufacturing of doses was already starting, Hancock said, so that it could be "rolled out" across the country when given the all-clear.

A vaccine would be a game-changer in combating the ovid-19 pandemic, giving vital protection particularly to the elderly and other vulnerable people, though it could take many months to roll out across the population, said the newspaper.

The UK may also be facing difficult months this autumn and winter seasons because Covid-19 cases and hospitalizations are expected to rise, though doctors have significantly improved care, raising hopes that the death rate will be far lower.

As of Tuesday, the UK has reported a total of 352,451 coronavirus cases, with 41,643 deaths.

--IANS

ksk/

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineBritain

First Published: Sep 08 2020 | 11:22 AM IST

Next Story